Navitoclax dalam kombinasi dengan Dabrafenib dan Trametinib menunjukkan keberkesanan dalam merawat melanoma mutan BRAF – Penasihat Terapi Kanser

Kandungan penuh artikel

Related News Axitinib Plus Octreotide Shows ‘Modest Efficacy’ in Advanced Extrapancreatic Neuroendocrine Tumors Perioperative SHR-A2102 Plus Adebrelimab Shows Promise for MIBC Chidamide Plus CHOP Shows Promising Activity in PTCL-TFH Combination treatment with dabrafenib, trametinib, and navitoclax has demonstrated activity in patients with BRAFV600-mutant, advanced melanoma, according to research presented at the ASCO Annual Meeting 2023. The combination produced a complete response (CR) rate of 20% in a phase 2 trial. However, the 3-drug combination did not improve maximal tumor regression when compared to treatment with dabrafenib and trametinib. The phase 2 trial (ClinicalTrials. gov Identifier: NCT01989585) included 50 patients with BRAFV600-mutant, advanced melanoma who had received prior treatment but could not have received BRAF inhibitors. Patients were randomly assigned to receive dabrafenib and trametinib (n=25) or navitoclax plus dabrafenib and trametinib (n=25). In both arms, patients received dabrafenib at 150 mg twice daily and trametinib at 2 mg daily. Patients in the triplet arm received navitoclax at a 150 mg daily lead-in dose, then a 225 mg daily dose. The objective response rate was 84% in the navitoclax arm and 80% in the dabrafenib-trametinib arm. The CR rate was 20% and 16%, respectively. The 20% CR rate in the navitoclax arm met prespecified criteria for success of the first primary endpoint. However, there was no significant difference in maximal tumor regression between the treatment arms, which meant the second primary endpoint was not met. The median maximal tumor regression was –68.8% in the navitoclax arm and –63.1% in the dabrafenib-trametinib arm (P =. 88). At a median follow-up of 27.4 months, the median progression-free survival was 20.9 months in the navitoclax arm and 21.7 months in the dabrafenib-trametinib arm. The 2-year overall survival rate was 74% in the navitoclax arm and 57% in the dabrafenib-trametinib arm. The most common treatment-related adverse events (TRAEs) in the navitoclax arm were nausea, diarrhea, and fatigue. The most common TRAEs in the dabrafenib-trametinib arm were nausea, fever, alanine transaminase increase, and aspartate aminotransferase increase. Two patients in each arm discontinued treatment due to TRAEs. Disclosures: This research was partly supported by Novartis and AbbVie. Some study authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of disclosures. Reference Eroglu Z, Mehnert JM, Giobbie-Hurder A, et al. Randomized phase II trial of dabrafenib and trametinib with or without navitoclax in patients (pts) with BRAF-mutant (MT) metastatic melanoma (MM) (CTEP P9466). ASCO 2023. June 2-6,2023. Abstract 9511. Axitinib Plus Octreotide Shows ‘Modest Efficacy’ in Advanced Extrapancreatic Neuroendocrine Tumors Perioperative SHR-A2102 Plus Adebrelimab Shows Promise for MIBC Chidamide Plus CHOP Shows Promising Activity in PTCL-TFH